Morpholine → Cyclopropyl-(2,4-dichloro-6-morpholin-4-yl-pyrimidin-5-yloxy)-acetic acid methyl ester
Reaktionsgleichung
[CH3:1][O:2][C:3](=[O:18])[CH:4]([CH:15]1[CH2:17][CH2:16]1)[O:5][C:6]1[C:7](Cl)=[N:8][C:9]([Cl:13])=[N:10][C:11]=1[Cl:12].C(N(CC)CC)C.[NH:26]1[CH2:31][CH2:30][O:29][CH2:28][CH2:27]1>>[CH3:1][O:2][C:3](=[O:18])[CH:4]([CH:15]1[CH2:17][CH2:16]1)[O:5][C:6]1[C:11]([Cl:12])=[N:10][C:9]([Cl:13])=[N:8][C:7]=1[N:26]1[CH2:31][CH2:30][O:29][CH2:28][CH2:27]1Komponenten
4
Versuchsvorschrift
To a suspension of cyclopropyl-(2,4,6-trichloro-pyrimidin-5-yloxy)-acetic acid methyl ester (224 mg, 0.72 mmol) in IMS (4 mL) was added triethylamine (150 μL, 1.08 mmol) followed by morpholine (63 μL, 0.72 mmol). The yellow solution was stirred for 2.5 hours at RT before being concentrated in vacuo. The resultant residue was purified by column chromatography (SiO2, gradient 0-20% ethyl acetate in cyclohexane) affording Cyclopropyl-(2,4-dichloro-6-morpholin-4-yl-pyrimidin-5-yloxy)-acetic acid methyl ester as a colourless gum (233 mg, 89%). 1H NMR (CDCl3): δ 3.99 (1H, d, J=9.54 Hz), 4.03-3.83 (4H, m), 3.80-3.75 (4H, m), 3.78 (3H, s), 1.32-1.21 (1H, m), 0.70-0.57 (2H, m), 0.52-0.45 (1H, m), 0.33-0.26 (1H, m).